Home / Market News / $HALO
fiscal.ai Corporate Catalyst Impact 55/100 ● negative

Morgan Stanley Downgrades Halozyme Therapeutics to Equalweight

Nov 11, 2026, 2:37 PM UTC · Primary ticker $HALO

Morgan Stanley downgraded Halozyme Therapeutics from Overweight to Equalweight, while simultaneously raising its price target from $105 to $109. This indicates a more cautious but still positive outlook on the company's stock, suggesting that while growth expectations may be tempered, the firm still sees some upside.

Morgan Stanley downgraded Halozyme Therapeutics from Overweight to Equalweight, signaling a reduced level of conviction in the stock's outperformance. Despite the downgrade, the price target was increased from $105 to $109, suggesting that while the immediate upside potential might be seen as more limited, the firm still acknowledges underlying value or improved fundamentals. This action primarily affects Halozyme Therapeutics, as it reflects a shift in a major investment bank's view. In the short term, this could lead to some selling pressure or a dampening of positive sentiment. Long-term implications depend on whether other analysts follow suit or if the company's performance justifies a more optimistic outlook. A key risk for traders is that the downgrade could signal a plateau in growth, while an opportunity lies in understanding the nuances of the raised price target, which might indicate a belief in steady, albeit slower, appreciation.

$HALO negative Analyst downgrade
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.